Connect with us

Technology

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

Published

1 year ago

on

Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash

Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center

PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets

Conference call and webcast to be held today, May 15th, at 8:30 AM EDT

NEW YORK, May 15, 2025 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and reported financial results for the quarter ended March 31, 2025.

Conference Call and Webcast

The webcast will take place on Thursday, May 15, 2025, at 8:30 AM and is accessible in the investor relations section of the Company’s website at pavmed.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “PAVmed Business Update” to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at pavmed.com.

Business Update Highlights

“PAVmed, having stabilized its corporate structure and balance sheet, is well positioned to aggressively execute its strategic vision as a diversified commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “Both Lucid and Veris are now well-capitalized through key upcoming milestones, and we expect PAVmed to directly benefit from their success. We have an established track record of seeking value throughout the life sciences sector, initially expanding from medical devices into diagnostics with Lucid, and then into digital health with Veris.   We now see a significant opportunity to leverage PAVmed’s infrastructure and further diversify its portfolio into the biopharma sector.  We are actively evaluating attractive clinical and late preclinical-stage assets and hope to launch a subsidiary in this sector in the near future.”

Highlights from the first quarter and recent weeks:

Lucid Diagnostics (link to press release) recognized $0.8 million in EsoGuard® Esophageal DNA Test revenue for 1Q25 and processed 3,034 EsoGuard tests.

Strengthened balance sheet with stock offerings netting approximately $30.6 million; ended 1Q25 with over $40 million in pro forma cash.Launched “Embrace the Future” campaign targeting gastroenterologists.Gained traction in cash-pay concierge medicine and employer markets sales channels.NCI-sponsored study showed EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, supporting expanded indication and may increase market opportunity.Veris restarted development of its implantable physiological monitor after completing a private placement financing.Veris completed pilot program with The Ohio State’s James Cancer Hospital and will soon launch long-term commercial and strategic partnership.PMX Incubator actively engaged with multiple potential strategic partners on PortIO.

Financial Results:

For the three months ended March 31, 2025, PAVmed’s revenues reflect subscription revenues from the Veris Cancer Care Platform. EsoGuard-related revenues are no longer consolidated with PAVmed’s results due to the deconsolidation effective September 10, 2024. PAVmed’s management service income from Lucid Diagnostics, amounting to $3.2 million post-deconsolidation, is reflected in Other Income. Operating expenses were approximately $5.5 million which include stock-based compensation expenses of $1.0 million. GAAP net income attributable to common stockholders was approximately $17.7 million, or $0.34 per common share on a diluted basis.As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company’s financial results, the Company’s non-GAAP adjusted loss was approximately $0.9 million or $(0.07) per common share.PAVmed had cash and cash equivalents of $2.7 million as of March 31, 2025, compared to $1.2 million as of December 31, 2024.The unaudited financial results for the three months ended March 31, 2025 were filed with the SEC on Form 10-Q on May 15, 2025, and are available at www.pavmed.com or www.sec.gov.

PAVmed Non-GAAP Measures

To supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months ended March 31, 2025, and 2024 are as follows:

Condensed Consolidated Statement of Operations (Unaudited)

For the three months ended

March 31,

2025

2024

(in thousands except per-share amounts)

Revenue

$                    8

$             1,010

Operating expenses

5,454

15,046

Other (Income) Expense

(24,069)

4,476

Net (Income) Loss

(18,623)

18,512

Net income (loss) per common share, diluted

$               0.34

$             (2.62)

Net income (loss) attributable to common stockholders

17,695

(22,788)

Preferred Stock dividends and deemed dividends

1,273

7,576

Net income (loss) as reported

18,968

(15,212)

Adjustments:

Depreciation and amortization expense1

43

586

Interest expense, net2

(4)

(56)

NCI ownership share of Interest and Depreciation adjustments

—

(131)

EBITDA

19,007

(14,813)

Other non-cash or financing related expenses:

Stock-based compensation expense3

930

1,882

Operating expenses issued in stock1

50

23

Change in FV equity method investments

(21,004)

—

Change in FV convertible debt2

49

2,163

Loss on debt extinguishment2

58

369

Debt modification expense

—

2,000

NCI ownership share of non-GAAP adjustments

—

(239)

Non-GAAP adjusted (loss)

$              (910)

$           (8,615)

Non-GAAP shares outstanding, basic and diluted

13,876

8,695

Non-GAAP adjusted (loss) income per share, basic and diluted

$(0.07)

$(0.99)

1

Included in general and administrative expenses in the financial statements.

2

Included in other income and expenses.

3

Stock-based compensation (“SBC”) expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:

 

Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses

(in thousands except per-share amounts)

For the three months ended

March 31,

2025

2024

Cost of revenue

$                  36

$             1,744

Stock-based compensation expense3

—

(36)

Net cost of revenue

36

1,708

Amortization of acquired intangible assets

—

372

Sales and marketing

247

4,311

Stock-based compensation expense3

(45)

(403)

Net sales and marketing

202

3,908

General and administrative

4,384

6,678

Depreciation expense

(43)

(214)

Operating expenses issued in stock

(50)

(23)

Stock-based compensation expense3

(796)

(1,078)

Net general and administrative

3,495

5,363

Research and development

787

1,941

Stock-based compensation expense3

(89)

(365)

Net research and development

698

1,576

Total operating expenses

5,454

15,046

Depreciation and amortization expense

(43)

(586)

Operating expenses issued in stock

(50)

(23)

Stock-based compensation expense3

(930)

(1,882)

Net operating expenses

$             4,431

$           12,555

About PAVmed and its Subsidiaries

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.

For more and for more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com. 

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s and Lucid’s common stock; PAVmed’s Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s and Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s and Lucid’s clinical and preclinical studies; whether and when PAVmed’s and Lucid’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and Lucid’s products once cleared and commercialized; PAVmed’s and Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s and Lucid’s future operations, see Part I, Item 1A, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-first-quarter-2025-financial-results-302456538.html

SOURCE PAVmed Inc.

Related Topics:
Continue Reading

Technology

NexBank Partners with MaxMyInterest to Expand Customer Relationships Nationwide

Published

43 minutes ago

on

October 28, 2026

By

Max members can apply for new NexBank high-yield money market accounts in as little as 2 minutes.

DALLAS and PORTSMOUTH, N.H., Oct. 28, 2026 /PRNewswire/ — NexBank, the banking subsidiary of NexBank Capital, Inc. and the largest privately held bank based in Texas, today announced its partnership with MaxMyInterest (Max), an intelligent cash management service for individual investors and financial advisors.

Through this partnership, consumers nationwide can now open the NexBank MaxMyInterest Money Market Account, a high-yield account available exclusively through Max. The account offers competitive rates and a streamlined application process.

Max helps depositors seamlessly distribute their cash balances across multiple bank accounts to earn more on their deposits by earning highly competitive yields while simultaneously benefiting from greater aggregate FDIC insurance coverage, one-click funds transfers, and consolidated tax reporting. Deposits at NexBank are insured by the FDIC up to $250,000 per depositor, for each account ownership category.

“We are proud to partner with NexBank to help expand its reach to all 50 states,” said Rachel Bourne, Head of Bank Partnerships at Max. “Together with NexBank, we can help clients earn competitive rates while keeping their deposits safely within the FDIC insurance limits in their own bank accounts.”

To find information about the NexBank MaxMyInterest Money Market Account, contact your financial advisor or visit MaxMyInterest.com.

About NexBank
NexBank is the largest privately held bank based in Texas with assets of $14 billion and a charter that dates to 1922. NexBank provides institutional banking, commercial banking, mortgage banking, and personal banking services to meet the needs of its clients, which include institutional clients, financial institutions, corporations, and consumers nationwide. NexBank is a subsidiary of NexBank Capital, Inc., a financial holding company. 

www.NexBank.com
Member FDIC | Equal Housing Lender

About Max
Max, a service of Six Trees Capital LLC, offers intelligent cash management solutions for individual investors and their financial advisors, enabling clients to earn competitive yields on their cash. Max’s patented technology helps customers reallocate funds among their checking and high-yield savings accounts to earn the highest yield while keeping their funds safe in their own FDIC-insured partner bank accounts. Banking services are provided by participating FDIC-insured banks, including NexBank. For more information, visit MaxMyInterest.com, MaxForAdvisors.com, or MaxForBanks.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nexbank-partners-with-maxmyinterest-to-expand-customer-relationships-nationwide-302921162.html

SOURCE NexBank; MaxMyInterest

Continue Reading

Technology

Risk Analytics Market worth $54.69 billion by 2031 – Report by MarketsandMarkets™

Published

43 minutes ago

on

October 28, 2026

By

DELRAY BEACH, Fla., Oct. 28, 2026 /PRNewswire/ — According to MarketsandMarkets™, the Risk Analytics Market is projected to grow from USD 35.68 billion in 2026 to USD 54.69 billion by 2031, at a CAGR of 8.9% during the forecast period.

Browse 350 market data Tables and 75 Figures spread through 420 Pages and in-depth TOC on ‘Risk Analytics Market – Global Forecast to 2031’

Risk Analytics Market Size & Forecast:

Market Size Available for Years: 2021–20312025 Market Size: USD 31.61 billion2026 Market Size: USD 35.68 billion2031 Projected Market Size: USD 54.69 billionCAGR (2026–2031): 8.9%

Risk Analytics Market Trends & Insights:

The market is driven by increasing adoption of predictive analytics, artificial intelligence, machine learning, quantitative risk modeling, fraud detection, stress testing, and integrated risk management platforms across banking, insurance, capital markets, and other industries.Software is estimated to account for 37.2% of the Risk Analytics Market in 2026.The technology risk segment is expected to register the fastest growth of 11.4% CAGR between 2026 and 2031.The healthcare & life sciences segment is expected to be the fastest-growing segment across the forecast period.North America is estimated to account for the largest regional share of 37.01% in 2026.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210662258

The expansion of the Risk Analytics Market is influenced by various factors, including the growing frequency and complexity of global risks, the increasing demand for efficient decision-making tools in companies, and technological advancements like artificial intelligence (AI) and machine learning (ML). Organizations across sectors such as finance, healthcare, and manufacturing are using risk analytics to anticipate potential disruptions and ensure regulatory compliance. The growing reliance on big data, combined with the rise in IoT devices, has expanded the volume of data available for analysis, enabling more precise risk evaluations. Moreover, rising cyber threats, coupled with demand for robust cybersecurity strategies, are driving the need for risk management solutions. Additionally, the evolving landscape of climate-related risks and natural disasters is prompting organizations to integrate climate risk models into their assessments. Together, these factors underscore the need for comprehensive, timely risk management strategies, making risk analytics an essential resource in today’s business landscape.

By software type, the Governance, Risk, and Compliance (GRC) software segment is expected to account for the largest market share during the forecast period (2026–2031).

Governance, Risk, and Compliance (GRC) software dominates the Risk Analytics Market because it helps organizations meet stringent regulatory demands and follow internal policies. GRC software is designed to ensure that organizations operate within legal and ethical boundaries while minimizing compliance risks. As regulations grow more complex and sector-specific across regions, businesses increasingly adopt GRC solutions to automate compliance monitoring, maintain audit readiness, and ensure transparency. These systems provide real-time tracking and reporting, enabling organizations to quickly detect non-compliance or policy breaches and implement corrective measures. Moreover, GRC platforms can consolidate and standardize compliance processes across departments, improving efficiency and reducing the risk of human error. As firms face rising costs from regulatory fines and reputational damage, the importance of robust GRC systems continues to grow, reinforcing their dominance in the risk analytics sector.

Request for Proposal: https://www.marketsandmarkets.com/requestsampleNew.asp?id=210662258

By risk type, strategic risk is projected to grow at the second-fastest rate in the Risk Analytics Market during the forecast period.

Strategic risk analytics is expected to gain importance as organizations address uncertainties related to market dynamics, competitive positioning, business diversification, and long-term sustainability. Increasing market volatility and interconnected business environments are driving the need to assess risks from market concentration, new product development, and expansion into unfamiliar markets. Digital transformation, evolving business models, and platform-based strategies also introduce interconnected risks that require systematic assessment and monitoring. Strategic initiatives such as mergers, partnerships, and business expansion can also expose organizations to financial, operational, and competitive uncertainties. Risk analytics supports these activities by enabling scenario analysis, predictive modeling, and data-driven evaluation of potential outcomes. These capabilities help organizations assess the implications of strategic decisions, identify emerging threats, and align risk management practices with business objectives.

By region, North America is estimated to account for the largest share of the Risk Analytics Market in 2026.

Regional demand is supported by the adoption of risk analytics across banking, insurance, healthcare, and other industries. Organizations in the region use these solutions for credit risk assessment, fraud detection, regulatory compliance, cybersecurity risk monitoring, and operational risk management. Regulatory frameworks, including Basel III and the Dodd-Frank Act, contribute to demand for risk measurement, reporting, and compliance solutions in the financial sector. The integration of artificial intelligence, machine learning, big data analytics, and cloud computing is expanding the application of risk analytics in risk identification, predictive modeling, and decision-making. The presence of established technology providers, financial institutions, and specialized analytics vendors also contributes to the development and adoption of risk analytics solutions across the region.

Request Pricing: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=210662258

Top Companies in Risk Analytics Market:

The Top Companies in Risk Analytics Market are Marsh McLennan (US), Aon (England), Deloitte (UK), Capgemini (France), Moody’s Analytics (US), IBM (US), Oracle (US), FIS (US), Lockton (US), SAS Institute (US), MetricStream (US), Milliman (US), and Protiviti (US).

Risk Analytics Market – Investment & funding + Merger & Acquisition

Investment And Funding Context

Investment activity in the Risk Analytics Market is increasingly focused on credit risk modeling, predictive analytics, regulatory compliance, fraud detection, and AI-enabled risk intelligence. In August 2026, ICRA Limited launched ICRA Risk & Analytics, bringing together ICRA Analytics, Fintellix, and D2K Technologies after completing acquisitions totaling USD 30.65 million. The platform was designed to address risk management, regulatory compliance, and data management requirements for financial institutions, regulators, and corporates.

Technology development and strategic collaborations also remained important in 2026. In April 2026, Moody’s announced the integration of its credit intelligence and analytical capabilities into Microsoft 365 Copilot workflows, expanding access to credit ratings, research, entity data, and related risk intelligence. In August 2026, Moody’s also announced that its intelligence was available through Google Cloud’s Gemini Enterprise for Financial Services. These developments show investment in integrating risk analytics with enterprise AI platforms rather than relying solely on standalone analytical systems.

Revenue Shift Context

Revenue generation in the Risk Analytics Market spans software subscriptions, analytical data, risk models, regulatory reporting solutions, and advisory services. Financial institutions and enterprises use these capabilities for credit assessment, market risk measurement, portfolio monitoring, fraud detection, and compliance management. In July 2026, FICO reported third-quarter fiscal 2026 revenue of USD 674.2 million, including USD 215.3 million from its Software segment, which covers analytics and digital decisioning technology. The company’s reported results demonstrate the commercial importance of software-based analytics and decisioning, although its total revenue also includes scoring solutions and should not be treated as Risk Analytics Market revenue alone.

Insurance-focused analytics also represents an important revenue source for providers serving property, casualty, and catastrophe risk applications. Verisk reported USD 806 million in revenue for the second quarter of 2026, up 4.3% year over year. However, this figure reflects company-wide revenue rather than revenue attributable exclusively to risk analytics. Accordingly, company financial results should be distinguished from revenue generated specifically within the Risk Analytics Market when evaluating competitive positions.

Mergers & Acquisitions

Direct mergers and acquisitions among pure-play risk analytics vendors remain selective, while strategic acquisitions and partnerships help companies expand their capabilities in risk modeling, financial data analytics, regulatory compliance, fraud detection, and enterprise risk management. Transactions and integrations in this market can strengthen proprietary data assets, analytical models, risk intelligence, and software capabilities. Companies also use acquisitions to expand their coverage of credit risk, insurance risk, operational risk, and regulatory reporting, enabling them to serve a broader range of financial institutions and enterprises.

Recent examples illustrate this trend. In July 2026, Moody’s expanded its partnership with Intapp by integrating credit risk assessments, entity screening, and ownership data into Intapp’s Celeste AI platform, supporting risk evaluation and due diligence workflows. In April 2026, Cartan Trade partnered with Moody’s to incorporate credit risk data, default-risk insights, beneficial ownership information, and media monitoring into its platform through APIs, supporting underwriting and credit-limit monitoring. In September 2026, Moody’s and Euler ILS Partners signed a multi-year agreement to use catastrophe risk models, cyber risk models, and exposure datasets for underwriting, portfolio management, and investment decisions in insurance-linked securities. These developments demonstrate how partnerships and integrations can expand access to risk intelligence, strengthen analytical workflows, and support risk assessment across credit, insurance, and catastrophe-related applications.

RISK ANALYTICS MARKET: MERGERS AND ACQUISITIONS, JANUARY 2026–OCTOBER 2026

Month & Year

Deal Type

Company 1

Company 2

Description

October 2026

Product Collaboration

Moody’s Analytics

Allvue Systems

The companies launched the EDF-X Private Credit Model, combining Moody’s credit risk modeling with Allvue’s private credit performance data to identify early indicators of borrower stress.

August 2026

Platform Launch Following Acquisitions

ICRA Limited

Fintellix and D2K Technologies

ICRA launched ICRA Risk & Analytics after completing acquisitions totaling INR 296.2 crore, consolidating its analytics, risk, and technology businesses under one platform.

August 2026

Strategic Integration

Moody’s

Google Cloud

Moody’s made its credit ratings, research, entity information, and risk intelligence available through Gemini Enterprise for Financial Services using its Credit Model Context Protocol server.

July 2026

Acquisition

Verisk

McKenzie Intelligence Services

Verisk announced the acquisition of McKenzie Intelligence Services to strengthen catastrophe preparation and response capabilities using geospatial intelligence and event-related analytics.

April 2026

Strategic Partnership / Integration

Moody’s

Microsoft

Moody’s expanded the integration of its credit intelligence, research, entity data, and analytical workflows into Microsoft 365 Copilot and related AI-powered enterprise tools.

Company Revenue Share Details

The top five companies account for approximately 32.6% of the Risk Analytics Market in 2025. The leading group comprises Marsh McLennan, Aon, Deloitte, Lockton, and Moody’s Analytics, reflecting their established presence across enterprise risk management, financial risk analytics, risk advisory, insurance analytics, and regulatory compliance. The leading companies differentiate themselves through their risk modeling capabilities, proprietary data assets, predictive analytics, credit risk assessment, and integration with enterprise risk management workflows. Marsh McLennan and Aon provide risk advisory and insurance-related analytics, while Deloitte and Lockton support organizations through risk consulting, exposure assessment, and mitigation strategies. Moody’s Analytics specializes in financial risk intelligence, credit risk modeling, economic forecasting, and stress testing. Other providers, including FICO, Verisk Analytics, SAS Institute, Oracle, and IBM, contribute to the competitive landscape through capabilities in credit scoring, insurance risk analytics, statistical modeling, and enterprise risk management.

Browse Adjacent Markets: Artificial Intelligence (AI) Market Research Reports & Consulting

Related Market Reports:

Smart Grid Analytics Market by Software Type (Meter analytics, Operational Analytics, Reliability Analytics), Application (AMI, Load Forecasting, Demand Response, Grid Optimization), Analytics Type (Predictive, Prescriptive) – Global Forecast to 2029

AI Model Risk Management Market Size, Share, Growth Analysis, By Offering (Software Type and Services), Application (Fraud Detection & Risk Reduction, Regulatory Compliance Monitoring), Risk Type, Vertical and Region – Global Industry Forecast to 2029

About MarketsandMarkets™ 

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/risk-analytics.asp

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/risk-analytics-market-worth-54-69-billion-by-2031–report-by-marketsandmarkets-302922043.html

Continue Reading

Technology

ManpowerGroup Elects Lidia Fonseca to its Board of Directors

Published

43 minutes ago

on

October 28, 2026

By

MILWAUKEE, Oct. 28, 2026 /PRNewswire/ — ManpowerGroup (NYSE: MAN) today announced the election of Lidia Fonseca, former Executive Vice President and Chief Digital and Technology Officer at Pfizer, to its Board of Directors, effective November 1, 2026.

“Lidia brings a rare combination of technology leadership, business transformation experience and a clear understanding of how AI can create value at scale,” said Jonas Prising, ManpowerGroup Chair & CEO. “Her strategic perspective, operational expertise and track record of leading change strengthen our ability to evolve the business and advance our transformation strategy. We are pleased to welcome her to our Board.”

Fonseca served as Chief Digital and Technology Officer and Executive Vice President of Pfizer from January 2019 to April 2026, leading the company’s enterprise AI, digital, data and technology strategy, as well as Learning & Development, and Business Process Excellence. She built Pfizer’s enterprise AI program from inception, and scaled it across the enterprise, contributing to significant growth and cost savings. She currently serves as Senior Advisor to Pfizer’s Chief Executive Officer and serves on the Board of Directors of Medtronic plc.

Previously, Fonseca spent a decade in diagnostics as Senior Vice President and Chief Information Officer of Quest Diagnostics and, earlier, of LabCorp. She began her career in operations and executive leadership roles at Philips Healthcare. Fonseca holds a bachelor’s degree from the University of California, Berkeley, and an MBA and a Master of Business Informatics from Rotterdam School of Management at Erasmus University.

ABOUT MANPOWERGROUP
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World’s Most Ethical Companies for the 17th time; all confirming our position as the brand of choice for in-demand talent.

For more information, visit www.manpowergroup.com, or follow us on LinkedIn, Facebook, and Bluesky.

View original content to download multimedia:https://www.prnewswire.com/news-releases/manpowergroup-elects-lidia-fonseca-to-its-board-of-directors-302921381.html

SOURCE ManpowerGroup

Continue Reading

Trending